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A B S T R A C T
Purpose
The association between established risk factors for breast cancer and subtypes or prognosis of the
disease is not well known. We analyzed whether the Tyrer-Cuzick–predicted 10-year breast cancer
risk score (TCRS), mammographic density (MD), and a 77-single nucleotide polymorphism polygenic
risk score (PRS) were associated with breast cancer tumor prognosticators and risk of distant
metastasis.
Patients and Methods
We used a case-only design in a population-based cohort of 5,500 Swedish patients with breast
cancer. Logistic and multinomial logistic regression of outcomes, estrogen receptor (ER) status, lymph
node involvement, tumor size, and gradewasperformedwith TCRS, PRS, and percentMDasexposures.
Cox proportional hazard models were used to estimate hazard ratios (HRs) of distant metastasis.
Results
Women at high risk for breast cancer based on PRS and/or TCRS were significantly more likely to be
diagnosed with favorable prognosticators, such as ER-positive and low-grade tumors. In contrast,
PRS weighted on ER-negative disease was associated with ER-negative tumors. When stratifying
by age, the associations of TCRS with favorable prognosticators were restricted to women younger
than age 50. Women scoring high in both TCRS and PRS had a lower risk of distant metastasis (HR,
0.69; 95% CI, 0.49 to 0.98). MD was not associated with any of the examined prognosticators.
Conclusion
Women at high risk for breast cancer based on genetic and lifestyle factors were significantly more
likely to be diagnosed with breast cancers with a favorable prognosis. Better knowledge of subtype-
specific risk factors could be vital for the success of prevention programs aimed at lowering
mortality.
J Clin Oncol 34:251-258. © 2015 by American Society of Clinical Oncology
INTRODUCTION
Breast cancer is a heterogeneous disease, with
both environmental and genetic causes. Currently
known risk factors can be used in prediction
modeling to identify women at risk for disease, a
necessary step for improving early detection, as
well as offering preventative interventions.1 The
Tyrer-Cuzick model has been developed to identify
women at increased risk for breast cancer, incor-
porating hormonal, lifestyle, and reproductive
risk factors, together with family history, in the
estimation of risk.2 Additionally, large-scale genome-
wide association studies have identified many
low-risk common variant single-nucleotide poly-
morphisms (SNPs) that partially explain disease
occurrence when analyzed as a polygenic risk score
(PRS). Recently, a PRS based on 77-SNP variants
was developed to predict breast cancer risk.3
Another factor used for risk prediction is mam-
mographic density (MD), one of the strongest risk
factors for breast cancer.4 These tools show future
promise for determining breast cancer risk in healthy
women, and their use has been suggested to improve
performance when used in combinations.5-8
Identification of women at high risk for
breast cancer is a pivotal part of successful clinical
prevention aimed at lowering disease mortality.
Importantly, if disease burden and mortality are
to be lowered, it is necessary to be able to identify
women at risk for all subtypes of the disease.
However, the prediction tools mentioned earlier
may be differentially associated with subtypes of
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the disease, given previous findings of separate etiologies for
distinct molecular subtypes of breast cancer.9-11 We investigated
whether Tyrer-Cuzick–predicted 10-year breast cancer risk score
(TCRS), PRS, and percent MD values differed, on average,
according to tumor prognosticators and metastasis in a large
population-based cohort of breast cancer patients in Sweden.
PATIENTS AND METHODS
All female breast cancer patients younger than 80 years of age diagnosed
between 2001 and 2008 in Stockholm-Gotland County, Sweden (n =
9,348) were invited to donate blood and answer a Web-based ques-
tionnaire. In all, 5,715 women (61%) consented and returned detailed
information regarding lifestyle, hormonal, and reproductive factors, as well
as consent to retrieve mammographic images. Women with a previous
breast cancer diagnosis (n = 215) were excluded from the study, leaving
5,500 women for analysis.
Tumor and patient characteristics were collected for all women by
links to the high-coverage Stockholm-Gotland Regional Breast Cancer
Quality Register.12 Lymph node involvement was dichotomized into
positive or negative. Tumor size was categorized into less than 20 mm, 20
to 40 mm, and greater than 40 mm in diameter. Estrogen receptor (ER)
status was recorded as negative or positive in the registers, determined by
radioimmunoassay or immunohistochemistry. Registry information was
essentially complete (98%) for tumor size and lymph node status, whereas
missing data were higher for ER status (80% complete). Grade was
available from 2004 onward, with 93% completeness.
The individual 10-year and 5-year risk of breast cancer was assessed at
age of diagnosis with the Tyrer-Cuzick model, using the International
Breast Cancer Intervention Study (IBIS) tool.2 Information on repro-
ductive, familial, anthropometric, and hormonal variables incorporated
was available in aWeb-based questionnaire, self-reported by the women on
study recruitment. Information on history of benign breast disease and
second-degree family history was not available in the data, yielding
potential underestimation of the risk. Data were 95% to 100% complete on
all used questionnaire variables.
Blood samples from participants were genotyped on a custom
Illumina iSelect Array (iCOGS Array) consisting of 211,155 selected SNPs.13
Missing genotypes were imputed using 1000 Genomes (phase I integrated
variant set release [v3] in National Center for Biotechnology Information
build 37 [hg19] coordinates). Full details of the construction of the PRS has
been described previously.14 The polygenic score for each patient was
evaluated using the PLINK command (–score), using weights reported in
Mavaddat et al.3 Three separate PRSs were constructed, corresponding to
weights from analyses on breast cancer overall (PRS), ER-negative disease
(PRS ER-negative), and ER-positive disease (PRS ER-positive).
Analog mammographic images were retrospectively collected from
five main radiology units. A prediagnostic analog film in the cancer-free
breast was available for 3,488 women. All mammographic images were
digitized with an Array 2905HD Laser Film Digitizer (Array, Tokyo, Japan).
Percent MD was assessed with an automated algorithm developed and
described by Li et al.15 The algorithm is trained to distinguish dense breast
areas from nondense areas by training on image segmentation data
measured through Cumulus.16 All study participants provided informed
consent, and the ethical committee at Karolinska Institutet approved the
study.
Statistical analysis was performed in R (version 3.1.0).17 Each sta-
tistical test was two-sided, with an alpha level set at .05. Any women with
missing information were excluded from analysis. Correlation coefficients
between the scores were calculated using Spearman’s rank method. The
binary outcomes, ER status and lymph node involvement, were modeled
with binomial logistic regression analysis. Multinomial logistic regression
(using the R “nnet”’ package) was used for the categorical outcomes of
grade and tumor size. The three risk prediction tools, MD, PRS, and TCRS,
were entered as standardized linear scores in all regression analyses. Each
score was modeled separately to assess its individual associations with the
outcomes. Analyses were performed overall, stratified by ER status, and
stratified by women younger than age 50 and 50 years or older. For PRS,
analysis was also done using PRS ER-negative and PRS ER-positive. All
analyses concerning MD were adjusted for age. For sensitivity analyses,
separate estimations were performed for women without a first-degree
relative with breast cancer (defined as mother or sister). Analysis using
TCRS 5-year estimates was also performed as a supplementary analysis
(Appendix Table A1 and A2, online only).
Cox proportional hazard regression models (using the R “survival”
package) were used to estimate hazard ratios (HRs) of distant metastasis
for each risk prediction tool, with time since diagnosis as the underlying
time scale. Subjects were followed from the date of diagnosis until the date
of distant metastasis, date of death from any cause, or end of follow-up on
September 12, 2014, whichever came first. Women with metastasis at the
time of diagnosis were excluded (n = 21). Information on the date of
metastasis was available from the Regional Breast Cancer Quality Register.
Date of death was merged from the annually updated, high-coverage
National Cause of Death Register. Comparisons were made between
women in the highest and the lowest quartile of the scores and between the
combination of PRS and TCRS, above versus below median, in both scores.
Three models were considered: model 1, only adjusting for calendar time;
model 2, adjusting for calendar time and age at diagnosis; and model 3,
further adjusting for tumor prognosticators. Schoenfeld residuals plotted
against time and a x2 test were used to assess the proportional hazards
assumption.
RESULTS
Descriptive statistics for the cohort are listed in Table 1. Of the
5,500 women, 5,232 had information on TCRS, 4,927 had
information on PRS, and 3,488 had a prediagnostic MD mea-
surement. Most women were postmenopausal (70%); the median
age was 59 years, with a range of 23 to 79 years. In the cohort, TCRS
ranged from 0.23% to 28.86%, with a median of 3.13% (standard
deviation [SD], 2.26%). Percent MD ranged from 0.001% to 91.5%,
with amedian of 19.19% (SD, 13.5%), and PRS ranged from20.0049
to 0.0154, with a median of 0.005 (SD, 0.002%). Spearman’s rank
correlation coefficient was 20.004 between TCRS and PRS, 20.12
between TCRS and MD, and 0.04 between PRS and MD.
Table 2 shows the results of binomial and multinomial logistic
regression of TCRS, PRS, and MD, overall and stratified by age.
TCRS was associated with ER status, grade, and lymph node
involvement (ER-negative odds ratio [OR], 0.80; 95% CI, 0.72 to
0.90; lymph node-positive OR, 0.77; 95% CI, 0.68 to 0.87; grade 3
OR, 0.79; 95% CI, 0.69 to 0.90; Table 2), but not with tumor size.
Associations remained in women younger than age 50 at diagnosis
but were not shown in women aged 50 to 79 years at diagnosis. On
finer age stratification, these effects were driven by associations in
women aged 40 years or younger (Appendix Table A1, online-only).
The PRS was associated with several prognosticators. Each
1-SD increase in the score was associated with smaller, low-grade,
hormone-positive tumors (ER-negative OR, 0.80; 95% CI, 0.74 to
0.87; tumor size greater than 40 mm OR, 0.86; 95% CI, 0.76 to
0.99; grade 3 OR, 0.86; 95% CI, 0.77 to 0.95; Table 2). In analyses
stratified by age at diagnosis, patterns of associations were similar
in both young and old women. MD was positively associated with
lymph node metastasis and tumor size in crude analysis, but
showed null associations with grade and ER status. After adjusting
252 © 2015 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
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for age at diagnosis, no prognosticator was associated with MD
(Table 2). Further adjustments for body mass index, hormone
replacement therapy use, and menopausal status did not change
estimates (not shown). In analyses stratified by age at diagnosis, no
distinct differences were observed (Table 2).
Table 3 shows the results from analyses of TCRS and MD by
ER status and of PRS weighted by ER-positive and ER-negative
disease. The same pattern was observed for TCRS among ER-
positive disease, as in the overall analysis, with a high score being
more common in low-grade, lymph node-negative patients.
Among ER-negative disease, no prognosticator was associated with
TCRS. Analysis using the ER-positive weighted PRS yielded point
estimates similar to the main PRS, whereas the ER-negative
weighted score was associated with ER-negative receptor status.
MD was not associated with any tumor characteristic in any of the
strata. There was a nonsignificant trend of high-grade cancer
among ER-negative patients with high MD (Table 3).
Sensitivity analysis using 5-year TCRS yielded results similar
to the main analysis using 10-year TCRS. The associations for both
scores were driven by effects among patients with early-onset disease
(Appendix Table A1, online-only). Sensitivity analysis excluding
women with a family history of breast cancer revealed more pro-
nounced effect sizes for TCRS, whereas no change was shown for
PRS or MD (Appendix Table A2, online-only).
Because TCRS and PRS were not correlated but showed
associations between ER and grade in the same direction, we
analyzed the combined effect of TCRS and PRS. Women scoring
above the median in both TCRS and PRS had more favorable
tumor characteristics than did those scoring below the median on
bothmeasures (ER-negative OR, 0.52; 95%CI, 0.41 to 0.66; grade 3
OR, 0.56; 95% CI, 0.43 to 0.78; Fig 1).
We further studied the combination of high TCRS and PRS on
the risk of being diagnosed with a distant metastasis. For women
scoring above themedian in both TCRS and PRS, an approximately
30% decreased risk of a distant metastasis was shown (HR, 0.69;
95% CI, 0.49 to 0.98; Table 4). The lowered risk was restricted to
patients younger than 50 years of age at diagnosis (HR, 0.20; 95%
CI, 0.05 to 0.84), with null associations in women aged 50 or older
(Table 4). Neither PRS nor MD were individually associated with a
risk of distant metastasis in our cohort, but there was a protective
effect for TCRS (HR, 0.69; 95% CI, 0.50 to 0.93), slightly atten-
uated by adjusting for age and prognosticators (Table 4). No
violations of the proportionality assumptions were shown.
DISCUSSION
For breast cancer risk prediction models to aid in lowering disease
mortality, they should ideally be able to predict both aggressive and
less aggressive subtypes of the disease. We found that women at
high risk for breast cancer based on the TCRS or PRS, or both, were
significantly more likely to be diagnosed with low-grade, ER-
positive cancers. TCRS was also associated with lymph node
involvement, and PRS was also influenced by tumor size. The
Table 1. Availability and Structure of Data for Age, Tyrer-Cuzick–Predicted 10-Year Risk Score, Polygenic Risk Score, and Mammographic Density in the Cohort
Characteristics Full Cohort
Women With Data
on TCRS
Women With
Data on PRS
Women With
Data on MD
Total No. of women (% missing data) 5,500 (0) 5,232 (5) 4,927 (10) 3,488 (36)
Age, years
, 50 1,114 (20) 1,048 (20) 924 (19) 489 (14)
$ 50 4,386 (80) 4,184 (80) 4,003 (81) 2,999 (86)
No. of postmenopausal women (% of total) 3,778 (70) 3,607 (70) 3,460 (71) 2,603 (75.5)
No. of women with positive family history (% of total) 1,010 (20) 993 (20) 915 (20) 628 (20)
BMI, kg/m2
, 20 228 (5) 222 (5) 207 (4) 136 (4)
20-24.9 2,313 (45) 2,279 (45) 2,155 (46) 1,481 (45)
$ 25 2,580 (50) 2,535 (50) 2,374 (50) 1,647 (51)
HRT use
Never 2,617 (58) 2,581 (58) 2,389 (57) 1,515 (53)
Past 988 (22) 970 (22) 938 (23) 702 (25)
Current 899 (20) 898 (20) 849 (20) 616 (22)
Estrogen receptor status
Negative 749 (16) 716 (16) 661 (16) 444 (15)
Positive 3,973 (84) 3,805 (84) 3,568 (84.5) 2,528 (85)
Lymph node status
Positive 551 (10) 519 (10) 478 (10) 304 (9)
Negative 4,908 (90) 4,675 (90) 4,414 (90) 3,174 (91)
Tumor size, mm
, 20 3,276 (64) 3,127 (65) 2,960 (65) 2,167 (66)
20-40 1,534 (30) 1,462 (30) 1,361 (30) 935 (29)
. 40 278 (6) 262 (5) 242 (5) 152 (5)
Grade
1 625 (19) 598 (19) 568 (19) 382 (20)
2 1,694 (52) 1,633 (52) 1,528 (52) 1,034 (53)
3 962 (29) 921 (29) 840 (29) 531 (27)
NOTE. Values are No. (% of total).
Abbreviations: BMI, bodymass index; ER, estrogen receptor; HRT, hormone replacement therapy;MD,mammographic density; PRS, polygenic risk score; TCRS, Tyrer-
Cuzick-predicted 10-year risk score.
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influence of PRS was age independent, in contrast to TCRS, which
was only associated with tumor characteristics in young women.
We further found that the risk of being diagnosed with distant
metastasis was significantly lower in women at increased risk for
breast cancer, according to both TCRS and PRS. MD showed null
associations with all tumor prognosticators under study and seems
therefore to be a general risk factor for breast cancer.
To the best of our knowledge, no study has previously
addressed how tumor prognosticators vary with the predicted
breast cancer risk using the Tyrer-Cuzick model. Several of the
lifestyle and reproductive risk factors determining the score have
been shown to be positively associated with ER-positive disease,10
in agreement with our results. We found that patients with a high
TCRS were more likely to have ER-positive tumors, and the largest
effect sizes were shown when excluding patients with a family
history of breast cancer, thus restricting the score to signifying
hormonal and lifestyle risk factors. Stratified analysis revealed that
these main effects were driven by associations in women younger
than 40 years of age. This suggests that risk factors incorporated in
the Tyrer-Cuzick model are less useful when aiming to identify
aggressive breast cancer in young women, but may work well as a
general tool for postmenopausal cancers. Moreover, if high-risk
young women according to TCRS are at risk for developing ER-
positive subtypes, TCRS could be a tool for identifying healthy
Grade 3
Grade 2
Tumor > 40 mm
Tumor 20–40 mm
Lymph spread
ER-negative
0.25 0.75 1.00 1.50 2.000.50
Odds Ratio
Tu
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Fig 1. Associations with tumor prognosticators in
women scoring above the median in polygenic risk score
(PRS) and Tyrer-Cuzick–predicted 10-year risk score
(TCRS) versus women scoring below the median in PRS
and TCRS. Shown are odds ratios with 95% confidence
intervals. ER, estrogen receptor.
Table 4. Cox Regression Modeling of Hazard Ratios of Distant Metastasis
No. of Events All Women No. of Events Women , 50 years No. of Events Women $ 50 years
Model 1*
TCRS 164 0.69 (0.50 to 0.93) 69 0.83 (0.38 to 1.82) 95 0.83 (0.54 to 1.25)
PRS 145 0.91 (0.66 to 1.26) 38 0.66 (0.35 to 1.25) 107 0.99 (0.68 to 1.45)
MD 85 1.13 (0.74 to 1.74) 18 0.50 (0.14 to 1.73) 67 1.17 (0.72 to 1.90)
TCRS/PRS combined 129 0.69 (0.49 to 0.98) 39 0.20 (0.05 to 0.84) 90 1.02 (0.66 to 1.53)
Model 2†
TCRS 164 0.74 (0.53 to 1.06) 69 0.98 (0.44 to 2.20) 95 0.82 (0.54 to 1.25)
PRS 145 0.90 (0.65 to 1.25) 38 0.66 (0.35 to 1.25) 107 0.99 (0.68 to 1.45)
MD 85 1.10 (0.68 to 1.76) 18 0.47 (0.13 to 1.64) 67 1.22 (0.74 to 2.02)
TCRS/PRS combined 129 0.80 (0.56 to 1.15) 39 0.23 (0.06 to 0.98) 90 1.01 (0.66 to 1.53)
Model 3‡
TCRS 164 0.73 (0.51 to 1.04) 69 1.10 (0.48 to 2.49) 95 0.68 (0.44 to 1.04)
PRS 145 0.91 (0.65 to 1.26) 38 0.66 (0.35 to 1.26) 107 1.04 (0.71 to 1.52)
MD 85 1.04 (0.64 to 1.69) 18 0.44 (0.12 to 1.65) 67 1.15 (0.69 to 1.51)
TCRS/PRS combined 129 0.81 (0.56 to 1.18) 39 0.26 (0.06 to 1.10) 90 0.93 (0.61 to 1.43)
NOTE. Values are No. of events or HR (95%CI). HRs are shown for overall analysis and stratified to old and youngwomen. TCRS, PRS, andMDHRs represent women in
the top quartile of the scores being compared with women in the lowest quartiles. For TCRS/PRS combined, HRs represent women above median of TCRS and PRS are
compared with women below median of TCRS and PRS. Boldface type indicates associations significant at alpha = 0.05.
Abbreviations: HR, hazard ratio; MD, mammographic density; PRS, polygenic risk score; TCRS, Tyrer-Cuzick–predicted 10-year risk score.
*Adjusted for calendar period.
†Adjusted for calendar period and age (continuous).
‡Adjusted for calendar period, age (continuous), estrogen receptor status, lymph node involvement, and tumor size. For TCRS, also adjusted for grade.
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women who could be offered prophylactic treatment with anti-
estrogens, such as tamoxifen.
Interestingly, associations with grade and lymph node status
remained within the strata of ER-positive cancers; thus, we
observed an effect beyond ER status. High-grade ER-positive
cancers are more often of the luminal B subtype, a type found
with younger age of onset, whereas low-grade ER-positive tumors
are commonly of the subtype luminal A.18 Given the over-
representation of luminal A breast cancers in most populations
in which the etiology has been studied, a bias among currently
known risk factors toward luminal A might explain the associa-
tions. The distribution of TCRS within molecular subtypes is of
great interest for addressing this hypothesis in future work.
The associations between the 77-SNP PRS and tumor
prognosticators are in agreement with the one previous study
addressing a similar question.19 In contrast to TCRS, the PRS
findings were independent of age. This would be expected with
genetic markers if they predict disease independent of age-of-onset
patterns. Beyond ER status, we also found an association with
tumor grade. This is not altogether surprising, because there is a
modest correlation between ER status and grade. When stratifying
our analysis by ER status, all associations with grade disappeared
within both strata (data not shown). The reason for the PRS bias
toward ER-positive tumors is likely because of the abundance of
ER-positive cancers in SNP discovery cohorts. Studies designed to
challenge this issue have identified SNPs associated with ER-
negative disease,20 and the ER-negative weighted PRS would be
an important tool to examine, in addition to the overall PRS, when
assessing individual risk.We found ER-negative weighted PRS to be
associated with ER-negative disease, thus showing potential as a
complement to the overall PRS score for identification of healthy
women at risk for aggressive disease.
Of the three risk prediction tools characterized in this study,
MD has been studied most thoroughly for associations with tumor
prognosticators. Our results are consistent with the outcome of a
meta-analysis on MD and ER status, showing null associations,21
and the null associations with lymph node involvement and size,
after adjusting for age, are consistent with most other published
literature.22 In our study, we could not replicate the previous
finding of an association between MD and an increased risk of ER-
negative breast cancer in young women.23
Both PRS and TCRS were associated with favorable tumor
prognosticators, and women scoring high in both tools may be
even more likely to have favorable disease outcomes, as judged by
effect sizes from combinatorial analysis. The survival analysis
supported these findings because women above the median in both
PRS and TCRS were at decreased risk of distant metastasis. Again,
the effects were constrained to women younger than age 50. In this
group, adjusting for standard prognosticators did not alter the
effect size substantially, although the statistical significance was
lost. Given that young patients are at highest risk of metastasis,24
our results warrant further investigation in future studies. How-
ever, this is the first study of TCRS/PRS and survival, and this
part of our results should be interpreted with caution until
replication in independent cohorts can be performed. Our
survival analysis suggests that young women at risk for
aggressive disease may be classified as low-risk women by both
TCRS/PRS prediction tools.
Our study has limitations that should be discussed. The
survivor bias arising from including women alive in 2009 might
influence our findings. We performed sensitivity analysis, restricting
to women diagnosed between 2004 and 2008, but saw no consid-
erable changes to point estimates. Moreover, we had no information
of history of benign breast disease, one of the components of the
Tyrer-Cuzick model. Although we do not believe that such a history
is associated with any of the tumor characteristics under study, this
should be kept in mind when comparing with future studies. Family
history was restricted to first-degree relatives, which could under-
estimate the effects of family history on risk. However, because the
Tyrer-Cuzick shows a high-penetrance genetic risk, the model
should not be sensitive to the loss of information on distant relatives.
Finally, our results are representative of a homogenous Scandinavian
population and may not translate to other ethnic groups and
geographical regions.
The main strengths of this work lie in the high quality of the
Swedish health registers, combined with the availability of automated
MD estimates, questionnaire data, and genotype information for each
patient.We addressed our study question in a population-based cohort
of breast cancer patients with a large number of participants, thereby
generating high external validity. The regional cancer register provides
near-complete information on tumor prognosticators and good
follow-up for distant metastasis; moreover, the completeness of the
cause of death register ensures reliable censoring information, and the
reader-independent MD measurements limit any observer bias.
In conclusion, to our knowledge, we showed for the first time
that a high risk of breast cancer, based on TCRS and PRS, is
associated with favorable tumor prognosticators and a reduced risk
of being diagnosed with distant metastasis. PRS weighted on ER-
negative disease should be considered for identifying women at risk
for aggressive disease. Our results support the hypothesis that
breast cancer subtypes have different etiologies and highlight the
need to identify risk factors separately for distinct breast cancer
subtypes and ages of onset. Better knowledge of subtype-specific
risk factors and understanding of disease etiology may be vital for
the success of primary prevention and screening programs aimed
at lowering mortality.
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GLOSSARY TERMS
Cox proportional hazards regression model: a statistical
model for regression analysis of censored survival data, examining the
relationship of censored survival distribution to one or more covariates.
This model produces a baseline survival curve, covariate coefficient
estimates with their standard errors, risk ratios, 95% CIs, and
significance levels.
hazard ratios: the ratio of the hazard rate in one group (eg, a group
of treated patients) to the hazard rate in another group (eg, an untreated
control group of patients). The hazard rate is the probability of a
specified event, such as death or cancer recurrence, occurring
during a short time interval. The hazard ratio, therefore, is a
measure of the relative probability of an event occurring at any
given point in time.
logistic regression analysis: a multivariable regression model in
which the log of the odds of a time-fixed outcome event (eg, 30-day
mortality) or other binary outcome is related to a linear equation.
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Appendix
Table A1. Binomial andMultinomial Logistic Regression of TCRS and TCRS5 Versus Tumor Prognosticators, Stratified by Age:# 40, 41 to 50, 51 to 60,. 60Modeled
per 1-SD Increase
TCRS TCRS5
Women # 40
(n = 298)
Women 41 to 50
(n = 1,063)
Women 51 to 60
(n = 1,785)
Women . 60
(n = 2,354)
Women # 40
(n = 298)
Women 41 to 50
(n = 1,063)
Women 51 to 60
(n = 1,785)
Women . 60
(n = 2,354)
ER positive 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
ER negative 0.37 (0.15 to 0.86) 0.99 (0.67 to 1.43) 0.90 (0.75 to 1.07) 0.89 (0.74 to 1.05) 0.20 (0.05 to 0.65) 0.93 (0.62 to 1.44) 0.90 (0.74 to 1.07) 0.89 (0.74 to 1.05)
Lymph node negative 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Lymph node positive 0.31 (0.10 to 0.81) 0.86 (0.62 to 1.11) 0.95 (0.77 to 1.12) 0.94 (0.78 to 1.10) 0.19 (0.04 to 0.70) 0.85 (0.59 to 1.13) 0.95 (0.76 to 1.13) 0.94 (0.78 to 1.09)
Tumor , 20 mm 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Tumor 20 to 40 mm 0.90 (0.42 to 1.91) 0.89 (0.73 to 1.10) 1.08 (0.97 to 1.21) 0.96 (0.86 to 1.07) 0.94 (0.34 to 2.62) 0.89 (0.71 to 1.11) 1.08 (0.97 to 1.22) 0.95 (0.85 to 1.06)
Tumor . 40 mm 1.04 (0.33 to 3.27) 0.69 (0.39 to 1.23) 1.05 (0.84 to 1.32) 1.14 (0.97 to 1.33) 1.20 (0.26 to 5.52) 0.67 (0.35 to 1.26) 1.06 (0.83 to 1.35) 1.16 (0.99 to 1.36)
Grade 1 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Grade 2 0.61 (0.13 to 2.87) 1.18 (0.72 to 1.92) 1.29 (1.03 to 1.63) 1.10 (0.87 to 1.18) 0.45 (0.06 to 3.45) 1.21 (0.70 to 2.08) 1.30 (1.02 to 1.65) 1.00 (0.86 to 1.16)
Grade 3 0.70 (0.16 to 3.00) 1.35 (0.81 to 2.25) 1.00 (0.77 to 1.30) 0.89 (0.73 to 1.07) 0.45 (0.07 to 3.14) 1.37 (0.78 to 2.43) 0.95 (0.72 to 1.26) 0.86 (0.71 to 1.03)
NOTE. Values are OR (95% CI). Boldface type indicates associations significant at alpha = 0.05.
Abbreviations: ER, estrogen receptor; OR, odds ratio; Ref, reference; SD, standard deviation; TCRS, Tyrer-Cuzick-predicted 10-year risk; TCRS5, Tyrer-Cuzick-predicted
5-year risk.
Table A2. Binomial and Multinomial Logistic Regression of Each Tool Versus Tumor Prognosticators in WomenWithout Family History: TCRS, PRS, and MDModeled
per 1-SD Increase
TCRS PRS MD
ER positive 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
ER negative 0.71 (0.56 to 0.89) 0.77 (0.70 to 0.84) 0.92 (0.81 to 1.04)
Lymph node negative 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Lymph node positive 0.43 (0.33 to 0.56) 1.01 (0.91 to 1.13) 1.07 (0.93 to 1.24)
Tumor , 20 mm 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Tumor 20 to 40 mm 0.96 (0.87 to 1.07) 0.95 (0.88 to 1.03) 1.07 (0.97 to 1.18)
Tumor . 40 mm 0.70 (0.48 to 0.99) 0.82 (0.70 to 0.95) 0.95 (0.77 to 1.18)
Grade 1 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Grade 2 1.01 (0.81 to 1.27) 1.03 (0.93 to 1.15) 0.98 (0.85 to 1.13)
Grade 3 0.43 (0.33 to 0.59) 0.85 (0.76 to 0.96) 0.89 (0.75 to 1.05)
NOTE. Values are OR (95% CI). MD is adjusted for age. Boldface type indicates associations significant at alpha = 0.05.
Abbreviations: ER, estrogen receptor; MD, mammographic density; OR, odds ratio; PRS, polygenic risk score; Ref, reference; SD, standard deviation; TCRS, Tyrer-
Cuzick predicted 10-year risk.
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